Effect of pretreatment with carbimazole on early outcome following radio-iodine (131I) therapy

Eur J Nucl Med. 1984;9(10):464-6. doi: 10.1007/BF00563170.

Abstract

Of a group of 55 thyrotoxic patients given therapeutic radio-iodine (131I), 24 were made euthyroid with carbimazole before 131I: the remainder were given 131I alone. Carbimazole was discontinued 5 days before 131I was administered. By 3 months after 131I treatment there was a greater incidence of hypothyroidism in the group given 131I alone (42% vs 25%), but a lower incidence of persistent thyrotoxicosis (16% vs 46%), (P less than 0.05). One year after treatment a similar proportion of each group had persistent thyrotoxicosis (21% vs 23%), but there remained a lower incidence of hypothyroidism in the group pretreated with carbimazole (25% vs 45%). It is suggested that pretreatment with carbimazole reduces the degree of radiation induced thyroid damage.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Carbimazole / therapeutic use*
  • Female
  • Humans
  • Hyperthyroidism / drug therapy*
  • Hyperthyroidism / radiotherapy
  • Hypothyroidism / etiology
  • Iodine Radioisotopes / therapeutic use*
  • Male
  • Middle Aged
  • Premedication*
  • Radiation-Protective Agents / therapeutic use
  • Thyroid Function Tests
  • Thyroid Gland / radiation effects
  • Time Factors

Substances

  • Iodine Radioisotopes
  • Radiation-Protective Agents
  • Carbimazole